CAR-NK cells: A promising cellular immunotherapy for cancer

Cytotoxic T cells are two types of immune cells that can kill target cells through similar cytotoxic mechanisms. With the remarkable success of chimeric antigen receptor (CAR)-engineered T (CAR-T) cells for treating haematological malignancies, there is a rapid growing interest in developing CAR-engineered NK (CAR-NK) cells for cancer therapy. Compared to CAR-T cells, CAR-NK cells could offer some significant advantages, including: (1) better safety, such as a lack or minimal cytokine release syndrome and neurotoxicity in autologous setting and graft-versus-host disease in allogenic setting, (2) multiple mechanisms for activating cytotoxic activity, and (3) high feasibility for 'off-the-shelf' manufacturing.…

• KI
  Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology

  Awards: P30-CA14051, Grant P30-CA14051
• NI
  National Institutes of Health

  Award: P30-CA14051
• NC
  National Cancer Institute

  Awards: P30-CA14051, CA14051, Koch Institute Support (core) Grant P30-CA14051, Grant P30-CA14051
• NC
  NIH Clinical Center

  Awards: NS104315, CA197605